- Conditions
- Kidney Transplant
- Interventions
- Infliximab, Methylprednisolone, Mycophenolate Mofetil, Tacrolimus, Thymoglobulin®, Acetaminophen, Loratadine, Placebo for Infliximab, Prednisone, Diphenhydramine
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 250
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Interventions
- carboplatin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Osteosarcoma
- Interventions
- Losartan, Sunitinib
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia
- Conditions
- Kidney Transplantation, Kidney Disease
- Interventions
- Alemtuzumab, Sirolimus, Tacrolimus, Kidney transplant, Methylprednisolone (or equivalent), Acetaminophen, Diphenhydramine, Trimethoprim (TMP)/Sulfa (Bactrim, Septra), Valgancyclovir, Acyclovir, Pentamidine, Clotrimazole, Nystatin
- Drug · Procedure
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Lung Cancer
- Interventions
- DOTAP:Chol-TUSC2, Erlotinib, Dexamethasone, Diphenhydramine
- Drug
- Lead sponsor
- Genprex, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Autonomic Failure, Orthostatic Hypotension
- Interventions
- Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
- Drug · Other · Dietary Supplement + 1 more
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Acute Lymphoblastic Leukemia With Failed Remission, B-cell Non Hodgkin Lymphoma, B Cell Leukemia
- Interventions
- CD19 specific Chimeric Antigen Receptor T Cell
- Biological
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Migraine, Migraine in Children
- Interventions
- 1/2 maintenance fluids, Ketorolac, Diphenhydramine, Prochlorperazine, bolus
- Other · Drug
- Lead sponsor
- Dayton Children's Hospital
- Other
- Eligibility
- 5 Years to 21 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Dayton, Ohio
- Conditions
- Dermatitis, Atopic
- Interventions
- Gel Cream
- Other
- Lead sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- High Point, North Carolina
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic
- Interventions
- FOLFIRNINOX, Losartan, 9-ING-41
- Drug
- Lead sponsor
- Colin D. Weekes, M.D., PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Boston, Massachusetts • Charlestown, Massachusetts + 1 more
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Non Hodgkin's Lymphoma
- Interventions
- CD19CAR/virus specific T cells, Benadryl and Tylenol
- Genetic · Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2031
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Glioblastoma
- Interventions
- Treatment Period 1, Treatment Period 2, Treatment Period 3, Treatment Period 4a
- Drug
- Lead sponsor
- SignPath Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland
- Conditions
- Stroke, Dye Allergy
- Interventions
- Emergent IV Dye Preparation
- Combination Product
- Lead sponsor
- Global Neurosciences Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
- Interventions
- High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
- Conditions
- Blood Cancer, Leukemia, Graft Versus Host Disease, Malignancy, CLL, NHL, Hodgkin's Disease, MDS
- Interventions
- non-myeloablative hematopoietic cell transplantation, Anti-Thymocyte Globulin, Cyclosporine, Mycophenolate Mofetil, G-CSF, Solumedrol, Acetaminophen, Diphenydramine, Hydrocortisone
- Procedure · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 12 Months and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2010
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma, Mixed Germ Cell Tumor, Yolk Sac Tumor, Childhood Teratoma, Malignant Germ Cell Neoplasm, Extragonadal Seminoma, Non-seminomatous Germ Cell Tumor, Seminoma
- Interventions
- paclitaxel, ifosfamide, cisplatin, pegylated G-CSF, G-CSF, carboplatin, etoposide phosphate, stem cell reinfusion
- Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 14 Years and older · Male only
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2031
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • La Jolla, California • Loma Linda, California + 61 more
- Conditions
- Pancreatic Cancer
- Interventions
- FOLFIRINOX, Losartan, Proton Beam Radiation
- Drug · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Benign Paroxysmal Positional Vertigo
- Interventions
- Meclizine, Epley Maneuver, Lorazepam, Diphenhydramine, Ondansetron
- Drug · Other
- Lead sponsor
- Lehigh Valley Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Allentown, Pennsylvania
- Conditions
- Non-small Cell Lung Cancer With STK11/LKB1 Mutation
- Interventions
- Daratumumab and Hyaluronidase-fihj, Pre-Intervention Medication, Post-Intervention Medication
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
- Interventions
- Sildenafil, Losartan, Sildenafil and Losartan, Placebo Oral Tablet
- Drug
- Lead sponsor
- Alicia Gerke
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant, Living Kidney Donor
- Interventions
- Polyclonal Regulatory T Cells, Everolimus, Tacrolimus, Mycophenolate mofetil, Mycophenolic acid, Acetaminophen, Diphenhydramine, Biopsy, Kidney, Blood Draw, Leukapheresis, IS regimen conversion
- Biological · Drug · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more
- Conditions
- Solid Tumour
- Interventions
- HLX07, Acetaminophen, dexamethasone, diphenhydramine, 5-HT3 inhibitor
- Drug
- Lead sponsor
- Henlix, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Fremont, California
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
- Interventions
- Losartan, Placebo
- Drug · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 13
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 8 more